PARIS–(COMMERCIAL THREAD) – Regulatory news:
Air Liquide (Paris: AI) is continuing to develop its home healthcare activity in Europe with the acquisition of Betamed SA, a major player in home healthcare in Poland. Betamed specializes in the care of patients with severe pathologies, at home or in its specialized clinic in ChorzÃ³w in Silesia. This acquisition allows the Group to strengthen its presence in Poland and expand its range of services to support patients suffering from complex forms of chronic diseases.
Founded in 2001 and managed by Beata Drzazga, Betamed SA is the Polish leader in home care for patients with severe pathologies, such as respiratory disease, stroke, heart disease, neuromuscular disease or paraplegia. The company supports 5,000 patients, and also manages a specialized clinic with more than 100 beds for dependent patients, adults and children, requiring mechanical ventilation. In 2020, Betamed SA achieved a turnover of almost 25 million euros.
Since 2012, Air Liquide has made several acquisitions in home healthcare in Poland, and is now a recognized player in home mechanical ventilation in the country. The acquisition of Betamed SA marks a new stage in the development of its home healthcare activity in Poland, as it allows the Group to offer its patients a wider, more diversified and complementary range of services across the entire care path, thanks to an extensive geographic presence. In addition to the expertise of the founder of Betamed SA, Beata Drzazga, Air Liquide Healthcare will rely on the existing teams to further develop its activity.
Diane schillag, member of the Air Liquide Group Executive Committee supervising the Healthcare branch, said: âWe are pleased to welcome the Betamed SA teams to Air Liquide Healthcare, recognized for their expertise in the monitoring and care of patients with severe pathologies. This operation will allow the Group to strengthen its offer and its presence in home healthcare in Poland, in line with the strategy that the Group is deploying in the rest of Europe. A major player in home healthcare, Air Liquide’s ambition is to best meet the needs of patients and healthcare professionals.
Air Liquide’s Home Healthcare business
Liquid air, the leading European player in home health care, provides prescription care for patients with chronic conditions such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea, Parkinson’s disease and diabetes. Alongside hospital care, this activity is being developed in the patient’s home, because it allows a better quality of life and a reduction in treatment costs. The home care business represents 50% of 2020 revenue from Air Liquide’s Healthcare business.
World leader in gases, technologies and services for Industry and Health, Air Liquide is present in 78 countries with approximately 64,500 employees and serves more than 3.8 million customers and patients. Oxygen, nitrogen and hydrogen are small molecules essential for life, matter and energy. They embody Air Liquide’s scientific territory and have been at the heart of the company’s activities since its creation in 1902.
Air Liquide’s ambition is to be a leader in its industry, to offer long-term performance and to contribute to sustainable development – with a strong commitment to climate change and the energy transition at the heart of its strategy. The company’s customer-centric transformation strategy aims for profitable, steady and responsible growth over the long term. It is based on operational excellence, selective investments, open innovation and a network organization set up by the Group around the world. Thanks to the commitment and inventiveness of its people, Air Liquide relies on the energy and environmental transition, health changes and digitalization, and brings more value to all of its stakeholders.
Air Liquide’s sales amounted to more than 20 billion euros in 2020. Air Liquide is listed on Euronext Paris (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indices.